CLEAR RESULTS FROM
A
ONCE‑DAILY
PILLSOTYKTU™ (deucravacitinib) 6mg pill

CLEAR RESULTS FROM
A
ONCE‑DAILY
PILLSOTYKTU™ (deucravacitinib) 6mg pill

CHANGE THE WAY YOU SEE
YOUR MODERATE TO SEVERE
PLAQUE PSORIASIS
If you've been thinking that you are not where you'd like to be with your moderate to severe plaque psoriasis, it may be time to consider a change. Take a look at these results for SOTYKTU, then think about scheduling a chat with your dermatologist to see if SOTYKTU may work for you.
TRAILBLAZING SKIN
CLEARANCE FROM A PILL
In two studies of moderate to severe plaque psoriasis, SOTYKTU was compared to placebo and Otezla® (apremilast). Of the 1684 adults in the studies, 841 received SOTYKTU, 421 received placebo, and 422 received Otezla. Patients were assessed at 16, 24, and 52 weeks after starting treatment.
The results? Clearer skin for more people taking SOTYKTU...
Your results may vary.
CLEAR OR
ALMOST CLEAR
skin for half of people taking SOTYKTU at 16 weeks
compared to placebo.
In one study, 50% of people taking SOTYKTU saw clear or almost
clear skin vs 9% taking placebo.
75%
CLEARER SKIN
For over half of people taking
SOTYKTU at 16 weeks
compared to placebo.
In one study, 53% of people taking SOTYKTU saw 75%
clearer skin vs 9% of people taking placebo.
Hypothetical SOTYKTU™ (deucravacitinib) patient with moderate to severe plaque psoriasis
MORE SKIN CLEARANCE THAN THE LEADING PILL*
NEARLY TWICE AS MANY PEOPLE had 90% clearer skin with SOTYKTU compared to the leading pill* in one study.
90%
CLEARER SKIN
At 24 weeks, 42% of people taking SOTYKTU saw 90% clearer skin vs 22% taking the leading pill* in one study.
In a second study, 90% skin clearance was seen by 32% of people taking SOTYKTU vs 20% of people taking the leading pill.*
*Otezla® (apremilast).
Hypothetical SOTYKTU™ (deucravacitinib) patient with moderate to severe plaque psoriasis
START LOVING YOUR SCALP
INSTEAD OF HIDING IT
If you have psoriasis plaques on your scalp, you know it can be a hard-to-treat area. It may be painful and can come with itching and flaking that can be embarrassing. The good news is, SOTYKTU has shown effective results for the scalp and may be the treatment option you've been looking for.
Example of moderate to severe plaque psoriasis on the scalp
SOTYKTU helped more people have a CLEARER SCALP compared to the leading pill.* You can tip your hat to that. Just look at the stats.
In one study, the percentage of people with a CLEAR OR ALMOST CLEAR SCALP at 16 weeks:
70%of people
SOTYKTU
39%of people
THE LEADING PILL*
In a second study, 60% of people taking SOTYKTU vs 37% of people taking the leading pill* saw a clear or almost clear scalp at 16 weeks.
No significant difference in fingernail psoriasis was seen vs placebo at 16 weeks.
Your results may vary.
*Otezla® (apremilast).
CLEARANCE RESPONSE MAINTAINED
AT 1 YEAR
In a study, 70% of people (83 out of 118) who were clear
or almost clear at Week 24 SUSTAINED THOSE
RESULTS AT 1 YEAR
RELIEF FROM A WIDE RANGE
OF SYMPTOMS
You may experience the pain, itching, burning, stinging, and skin tightness associated with moderate to severe plaque psoriasis. But the discomfort may be combined with frustration if your symptoms are making it difficult to go about your daily life.
In studies, more adults on SOTYKTU (8% vs 1% for placebo) reported relief of bothersome symptoms of moderate to severe plaque psoriasis at 16 weeks compared to placebo.
Study results for relief of symptoms when taking SOTYKTU™ (deucravacitinib) vs placebo
Your results may vary.
There was no significant difference in complete relief from bothersome symptoms vs the leading pill at 16 weeks.*
There was no significant difference in complete relief from bothersome symptoms vs the leading pill at 16 weeks.*

*Otezla® (apremilast).
Your results may vary.
GET A CLOSER LOOK AT SOTYKTU
SOTYKTU works differently* than other treatments.
Want to see how SOTYKTU works inside the body?
*Selective TYK2 inhibitor.
1787-US-2200571 09/22
SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
All other trademarks are property of their respective owners.
© 2022 Bristol-Myers Squibb Company.
1787-US-2200141 09/22
This website is intended for U.S. residents
18 years of age or older.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.